MRTX - Mirati's Krazati gets EU conditional approval for lung cancer
2024-01-10 09:30:57 ET
More on Mirati Therapeutics
- Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition
- Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires
- Mirati lung cancer therapy endorsed in EU
- Seeking Alpha’s Quant Rating on Mirati Therapeutics
- Historical earnings data for Mirati Therapeutics
For further details see:
Mirati's Krazati gets EU conditional approval for lung cancer